A non-opioid designer molecule for treating chronic neuropathic pain has had promising results in a preclinical study conducted by researchers at Weill Cornell Medicine and the Burke Neurological Institute.
Only one in five Medicaid enrollees diagnosed with hepatitis C virus started treatment, according to a retrospective study led by researchers at Weill Cornell Medicine and Cornell University’s Ithaca campus.
An interdisciplinary Cornell team has identified a new mechanism regulating tumor growth in the skeleton, the primary site of breast cancer metastasis: mineralization of the bone matrix.
Weill Cornell Medicine associate professor Gregory F. Sonnenberg has been awarded a five-year, $3.26 million grant from the National Institutes of Health to investigate the underlying mechanisms of inflammatory bowel disease.
A multi-institution team led by a Weill Cornell Medicine scientist has been approved for $30 million in funding from the Patient-Centered Outcomes Research Institute to study heart procedure outcomes in underrepresented groups.
During the COVID-19 pandemic, many U.S. hospitals had overcapacity intensive care units while other area hospitals had open ICU beds available, a phenomenon known as “load imbalance.”
Using an innovative method for measuring doctor turnover, Weill Cornell Medicine researchers determined that between 2010 and 2018, the annual rate at which physicians left their practices increased by 43%, from 5.3% to 7.6% a year.
Weill Cornell Medicine and Columbia University have been awarded a five-year, $9.8 million grant from the National Cancer Institute to help combat cancer disparities fueled by persistent poverty.
An atlas that catalogues gene activity and the levels of small molecules called metabolites in tumor samples offers a new way of identifying the deep mechanisms of cancer.
